therapeutic developments. Nonetheless, significant controversies remain, and these controversies can cause major disagreement among experts. This issue of JNCCN proves this point and also illustrates the importance that we in the medical community must place
Search Results
Ovarian Cancer Guidelines: Treatment Progress and Controversies
Robert J. Morgan Jr.
Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia
Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre, and James Rosberg
disease response or tumor type: results from a prospective community oncology study. Procrit Study Group . J Clin Oncol 1998 ; 16 : 3412 – 3425 . 10 Gabrilove JL Cleeland CS Livingston RB . Clinical evaluation of once-weekly dosing of
Accelerating Advances in Cancer Care Research: A Lookback at the 21st Century Cures Act in 2020
Leigh Gallo, Ronald S. Walters, Jeff Allen, Jenny Ahlstrom, Clay Alspach, Yelak Biru, Alyssa Schatz, Kara Martin, and Robert W. Carlson
–agnostic approvals that were based on common genetic alterations rather than the tissue of origin. The OCE coordinated work across the various medical product centers throughout the FDA, and with the cancer research community, to make these advancements possible
NCCN Policy Summit: Cancer Care in the Workplace: Building a 21st Century Workplace for Patients, Survivors, and Caretakers
Victoria Hood, Lindsey Bandini, Taneal Carter, Alyssa Schatz, John Sweetenham, Warren Smedley, Joanna Fawzy Morales, Rebecca V. Nellis, Randy A. Jones, Lynn Zonakis, and Robert W. Carlson
Community, agreed that navigation and support are critical, because benefits are often difficult for individuals to understand and navigate. Panelists also emphasized the importance of considering long-term rather than just short-term costs when
Neutrophil Biology and the Next Generation of Myeloid Growth Factors
David C. Dale
candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors . Transfusion 2002 ; 42 : 1414 – 1421 . 57 Ofran Y Avivi I Oliven A . Granulocyte transfusions for
Are NCI Cancer Centers Providing Adolescents and Young Adults With Cancer Focused Clinical Services? A National Survey
Katherine Daunov, Michael Daunov, Kara Noskoff, Hilary Gan, Simon Davies, Megan Farrell, Whitney Hadley, Amelia Baffa, Jennifer Giesel, Rachel Egler, Alex Y. Huang, John J. Letterio, and Richard T. Lee
centers (7%) offered referral to a community fertility clinic not affiliated with their center. Most (78%) provided services if requested by patients. To a lesser extent, respondents reported sexual health being addressed in the survivorship phase (47%) or
How Have Multigene Panels Changed the Clinical Practice of Genetic Counseling and Testing
Robert Pilarski
and counseling. 28 Community Education Although panel testing has certainly moved clinical practice forward in many ways, it has also introduced its own set of problems that highlight the need for education of community practitioners on the
HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Maral DerSarkissian, Shuanglian Li, Aaron Galaznik, Rachel Bhak, Iryna Bocharova, Thomas Kulalert, Huamao M. Lin, Hui Huang, and Mei Sheng Duh
: Flatiron Health electronic health record data, largely from community oncology practices, from January 2011–April 2018 were used for this retrospective observational study. Treatment-naïve (TN) and relapsed/refractory (RR) second-line patients diagnosed
QIM19-142: Development of a Low Resource Tool for Improving Head and Neck Cancer Treatment Delivery Within an Integrated Health Care Delivery System
Vlad Sandulache, Anita Sabichi, George Chen, and Scott Charnitsky
designed to streamline cancer diagnosis and treatment. Head and neck cancer (HNC) remains a difficult disease to diagnose and treat. Delivery of multimodality treatment for advanced HNC is challenging at both academic centers and in the community setting
Access to and Appropriateness of Cancer Care: Who Decides?
William T. McGivney
clinicians and on the judgement of experts, in particular. To some extent, the clinical community brought this situation on itself with the variations in care and unnecessary procedure rates that were documented in the late 1980s. Now, unfortunately, the
